Filana Therapeutics Q3 2026 Results: Net Loss of $10.7M, Loss Narrows
Filana Therapeutics reported a net loss of $10.7 million for the third quarter of 2026, with a significant reduction in nine-month operating expenses compared to the prior year. The company received a Nasdaq deficiency notice regarding its share price but maintains a cash position of $78.2 million, which management believes is sufficient for at least the next 12 months.
- Key figure
- Net loss $10.7M